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Abstract 
Sensitive high-performance liquid chromatographic assays have been developed to determine the levels of the lactone and 
lactone plus carboxylate (total) forms of the antitumor agent irinotecan (CPT-11) and its active metabolite SN-38, in human 
plasma. The related compound camptothecin was used as the internal standard. The selective sample pretreatment for the 
lactone forms involved a single solvent extraction with acetonitrile-n-butyl chloride (1:4, v/v), whereas the sample clean-up 
for the total forms was a simple protein precipitation with aqueous perchloric acid-methanol (1:1, v/v), which results in the 
conversion of the carboxylate to the lactone forms. Chromatography was carried out on a Hypersil ODS column, with 
detection performed fluorimetrically. The methods have been validated, and stability tests under various conditions have 
been performed. The lower limits of quantitation are 0.5 and 2.0 ng/ml for the lactone and total forms, respectively. The 
assays have been used in a single pharmacokinetic experiment in a patient o investigate the applicability of the method in 
vivo. © 1997 Elsevier Science B.V. 
Keywords: Irinotecan; CPT- 11 ; SN-38 
1. Introduction 
Irinotecan (7-ethyl- 10-[4-(1-piperidino)- 1- 
piperidino]carbonyloxycamptothecin; CPT- 11) (Fig. 
1) is a synthetic derivative of the plant alkaloid 
camptothecin with increased aqueous olubility, that 
does not produce hemorrhagic ystitis associated 
with the parent compound [1]. CPT-11 has demon- 
strated pronounced antitumor activity against a vari- 
ety of experimental tumors [2-5]. The mechanism of 
Corresponding author. 
action of CPT- 11 involves inhibition of mammalian 
DNA topoisomerase-I [6,7], causing stabilization of 
cleavable complexes during DNA replication, tran- 
scription and repair, and, ultimately, cell death [8-  
ill. 
Extensive preclinical studies have shown that 
CPT-11 is in vivo rapidly converted into an active 
metabolite (7-ethyl- 10-hydroxycamptothecin; SN- 
38) (Fig. 1) via endogenous carboxylesterases in the 
intestinal mucosa, plasma and liver [12]. In vitro 
studies demonstrated that SN-38 is significantly more 
cytotoxic than CPT-I 1 [13,14]. Similar to all other 
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Fig. 1. Chemical structures ofthe lactone and carboxylate forms 
of CPT-11, its active metabolite SN-38, and the related compound 
CPT (used as internal standard for the HPLC assay). 
camptothecin analogues, CPT-11 and SN-38 can 
undergo a reversible, pH-dependent hydrolysis in 
which the closed lactone form is converted to the 
open carboxylate form and vice versa [15]. 
Initial pharmacokinetic studies of CPT- 11 in- 
volved assays based on high-performance liquid 
chromatography (HPLC) that measured only total 
levels, i.e. lactone plus carboxylate forms, of CPT-11 
and SN-38 [16-21]. In more recent clinical trials 
attempts have been made to carefully detail the 
complex pharmacokinetics of the lactone and car- 
boxylate forms by implementation f more selective 
assays that can discriminate between the two forms 
of both compounds [22]. The availability of such 
analytical methods is particularly important as only 
the closed lactone forms of CPT-11 and SN-38 are 
active as antitumor agents [23]. 
We now report on the development and validation 
of new, simplified and sensitive methods for the 
determination f the lactone and total forms of CPT- 
11 and SN-38 in human plasma. Compared to 
previously described methods, the assay sensitivity 
has been significantly improved with reproducible 
lower limits of quantitation of 0.5 ng/ml for CPT-11 
and SN-38 lactone in plasma. The usefulness of the 
analytical method was subsequently tested by the 
determination of CPT-11 and SN-38 in plasma 
samples from a patient with advanced colorectal 
cancer given CPT-11 by a 90-rain intravenous 
infusion. 
2. Experimental 
2.1. Chemicals 
CPT-11 (batch KO16; purity 99.6%) and SN-38 
(batch LIE 783; purity: 100%) were kindly donated 
by Rhrne-Poulenc Rorer (Vitry-sur-Seine Cedex, 
France). The internal standard camptothecin (CPT; 
batch 93K05A; purity 100%) was obtained from 
Pharmacia (New Mexico, USA). Acetonitrile, n- 
butylchloride, dimethyl sulfoxide (DMSO) and 
methanol were purchased from Rathburn (Walk- 
erburn, UK). Ammonium acetate, hydrochloric acid 
and perchloric acid were obtained from Baker (De- 
venter, The Netherlands) and sodium chloride from 
Merck (Darmstadt, Germany). Tetrabutylammonium 
sulphate came from Serva (Heidelberg, Germany). 
All chemicals were of the highest purity available 
and were used as received. Lyophilized type IX-A 
[3-o-glucuronide glucuronosohydrolase (EC 3.2.1.31 
from Escherichia coli; activity 1560 000 units/g) 
was purchased from Sigma (St. Louis, MO, USA). 
Throughout he study filtered and deionized water 
obtained from a Milli-Q system was used (Millipore, 
Milford, USA). Blank human plasma was obtained 
from healthy volunteers via the Central Laboratory 
of the Blood Transfusion Service (Amsterdam, The 
Netherlands). 
2.2. Drug solutions 
Separate stock solutions of CPT-11, SN-38 and 
CPT (at 1.00 mg/ml each) were prepared in triplicate 
by dissolving the appropriate amount of the drug, 
accurately weighed, in 10.0 ml of DMSO. A mixture 
of CPT-11 and SN-38 was obtained by dilution of 
the standard solutions in DMSO, yielding a final 
concentration of 20 Ixg/ml for both compounds. 
Working solutions for the lactone forms of CPT-1 l 
and SN-38 were prepared aily at 10, 20, 50, 100, 
200 and 300 ng/ml by serial dilution in a mixture of 
methanol-0.01 M aqueous hydrochloric acid (2:3, 
v/v) from the stock mixture. Similarly, working 
solutions for CPT-11 and SN-38 total were made at 
concentrations of 80, 200, 800, 2000, 4000 and 8000 
ng/ml. Spiked human plasma samples used for the 
construction of calibration curves were prepared by 
addition of 25 or 50 ~1 of the methanolic working 
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solutions to 1000 ~l q.i.d, of drug-free human 
plasma to obtain standards of 0.5, l, 2.5, 5, 10 and 
15 ng/ml for CPT-11 and SN-38 lactone, and 2, 5, 
20, 50, 100 and 200 ng/ml for CPT-11 and SN-38 
total. 
Drug solutions for interference analysis were 
obtained from the hospital pharmacy, either as 
solutions or after dissolving solid material in saline, 
e.g. tablets or capsules (final concentration: 1.0-50 
~g/ml in plasma). 
2.3. Sample pretreatment 
All frozen samples were thawed at 4°C in a 
water-bath and were homogenized by vortex-mixing. 
For determination of the lactone forms of CPT-11 
and SN-38, the internal standard CPT (100 ~1 of 25 
ng/ml in methanol-0.01 M aqueous hydrochloric 
acid (2:3, v/v)) and 0.8 g of solid sodium chloride 
were added to 1000 Ixl of human plasma in a 12-ml 
glass tube supplied with PTFE-covered screw caps. 
The samples were extracted with 7.5 ml of acetoni- 
trile-n-butyl chloride (1:4, v/v) by vigorous mixing 
for 5 rain, followed by centrifugation at4000 g for 2 
rain. The resulting els were broken by a fast manual 
rotation of the tubes, and next, the layers were 
allowed to separate again by centrifugation at4000 g 
for 5 min. The organic layer was pipetted into a 
clean glass tube containing 50 Ixl of DMSO, and 
dried at 60°C under a gentle stream of nitrogen, until 
a volume of approximately 50 Ixl remained. This 
residue was reconstituted in 100 t~1 of methanol and 
100 Ixl of perchloric acid-water (1:500, v/v) by 
vortex-mixing for 5 s, and samples of 100 p~l were 
injected into the HPLC system. 
For determination of CPT-11 and SN-38 total, a 
250-1xl aliquot of plasma was mixed for 10 min with 
500 I~1 of cold (-20°C) perchloric acid-water- 
methanol (1:20:20, v/v/v) in 1.5-ml polypropylene 
tubes (Eppendorf, Hamburg, Germany). After cen- 
trifugation for 5 min at 24 000 g, 100 I~1 of the clear 
supernatant were injected into the HPLC system 
from autosampler vials with polypropylene inserts. 
2.4. HPLC instrumentation a d equipment 
The chromatographic equipment consisted of a 
constaMetric 4100 solvent delivery system, an au- 
toMetric 4100 autosampling device and a 
fluoriMonitor 4100 fluorescence detector (all from 
LDC Analytical, Rivera Beach, USA). A stainless 
steel (100X4.6 mm I.D.) analytical column packed 
with 5 ~m Hypersil ODS material (LC Service, 
Emmen, The Netherlands), protected by a LiCh- 
roCART 4-4 endcapped pre-column (4x4 mm I.D.) 
packed with 5 ~m LiChrospher 100 RP-18 material 
(Merck), was used for chromatographic separation. 
The analytical columns were maintained at a tem- 
perature of 50°C using a Model SpH99 column oven 
(Spark Holland, Meppel, The Netherlands). The 
mobile phases were composed of methanol-0.1 M 
ammonium acetate containing 0.01 M tetrabutylam- 
monium sulphate (40:60 (v/v) for the assay of the 
lactone forms and 35:65 (v/v) for the assay of the 
total forms), with the pH adjusted to 5.50 using 
hydrochloric acid. Prior to use, the mobile phases 
were filtered under reduced pressure through a 0.45- 
Ixm cellulosic acetate filter (Millipore), and degassed 
by ultrasonication. The mobile phases were delivered 
isocratically at a flow-rate set at 1.00 ml/min, and 
the column eluent was monitored fluorimetrically at 
an excitation wavelength of 355 nm and an emission 
wavelength of 515 nm, with a bandwidth of 30 nm. 
Detection and integration of chromatographic 
peaks was performed by the Fisons ChromCard ata 
analysis system (Milan, Italy), connected to an ICW 
workstation. Calibration curves were computed using 
the ratio of the peak height of CPT-I 1 or SN-38 and 
the internal standard versus the nominal concen- 
tration (x), by using weighted (1/x:) least squares 
linear-regression a alysis. 
2.5. Precision and accuracy 
A validation run of human plasma samples in- 
cluded the six-point calibration curves in duplicate 
and determination f quality control (QC) samples at 
four to five concentrations (spiked at 2, 7.5, 12, 120 
and 5000 ng/ml for the lactone forms, and at 10, 75, 
150 and 750 ng/ml for the total forms) of both 
CPT-11 and SN-38 in quintuplicate. The QC samples 
containing the highest concentration of CPT-ll and 
SN-38 were used to investigate the effect of sample 
dilution and/or limited volume injection. The com- 
plete validation procedure was performed on four 
separate days. The precision and accuracy of the 
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assays was assessed by the between-day and within- 
day precision and the percentage deviation (% DEV) 
from the nominal concentrations, respectively. Esti- 
mates of the between-day precision were obtained by 
one-way analysis of variance (ANOVA) using the run 
day as the classification variable. The between- 
groups mean square (MSbet), the within-groups mean 
square (MSwit) and the grand mean (GM) of the 
observed concentrations across run days were calcu- 
lated using the NCSS package (Version 5.0, J.L. 
Hinze, East Kaysville, USA; 1991). The between- 
day precision, expressed as percentage R.S.D., was 
defined as: 
Between-day precision = 100(SDd~y/GM) (1) 
SDaay=l(MSbet_MSwit)lnlO.Sr... and n repre- where 
sents the number of replicates within each run. For 
each concentration, the estimate of the within-day 
precision, also expressed as R.S.D. (%), was calcu- 
lated: 
05 Within-day precision = 100[(MSwi t) " /GM] (2) 
2. 7. Extraction recovery 
The recovery of CPT-11 and SN-38 was estab- 
lished at concentrations of 0.5, 1, 2.5, 5, 10 and 15 
ng/ml for the lactone forms, and of 2, 5, 20, 50, 100 
and 200 ng/ml for the total forms, by comparing 
peak areas of samples prepared in plasma with those 
for non-processed samples prepared in the mobile 
phase. The recovery was determined in four ana- 
lytical runs. 
2.8. Specificity and selectivity 
The interference from endogenous components 
was investigated by the analysis of six different 
blank human plasma samples in duplicate. The 
following substances were investigated for interfer- 
ence with the analytical methods: acetaminophen, 
alizapride, codeine, dexamethasone, domperidon, 
metoclopramide, morphine and ranitidine. 
2.9. Stability 
In cases where the MSwi t is greater than the 
MSbet, the resulting variance estimate is negative, 
implying that no significant additional variation was 
observed as a result of performing the assay on 
different days. The accuracy or mean percentage 
DEV for each concentration was calculated as: 
Mean %DEV = 100(mean conc 
- nominal conc/nominal conc) (3) 
2.6. Lower limit of quantitation 
For determination of the lowest standard con- 
centration in the analytical run quantitated with a 
definite level of certainty, i.e. the lower limit of 
quantitation (LLQ), plasma samples of five indi- 
viduals were spiked at 0.25 and 0.5 ng/ml, and at 1.0 
and 2.0 ng/ml for the lactone and total forms of 
CPT-11 and SN-38, respectively. For the concen- 
tration to be accepted as the LLQ, the mean per- 
centage DEV of at least 80% of the samples assayed 
should be -<20%, with a resulting within-day preci- 
sion of -<20%. 
The stability of the lactone and total forms of 
CPT-11 and SN-38 was evaluated at -80°C for two 
months, and at 37°C for 20 h using the concen- 
trations of the QC samples. After the storage period, 
the samples were analyzed immediately. The stabili- 
ty of both compounds was also investigated separ- 
ately at lactone and total concentrations of 7.5 and 
150 ng/ml, respectively, at(i) room temperature and 
(ii) five consecutive freeze-thaw cycles. 
2.10. Analysis of patient samples 
Fourteen plasma samples from a male patient 
treated for advanced colorectal cancer with a 90-min 
intravenous infusion of 200 mg/m 2 of CPT-11 
followed by a 3-h intravenous infusion of 60 mg/m 2 
of cisplatin have been analyzed. The samples were 
taken immediately before infusion, at 30 min and 3 h 
after beginning of the infusion and at 10, 20 and 30 
min and l, 1.5, 2, 4, 5, 8.5, 24 and 32 h post- 
infusion. The blood samples were collected in 
heparinized tubes, and cells were directly separated 
by centrifugation. The plasma supernatant was kept 
at -20°C, until storage at -80°C within 2 h. 
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Thawing of the samples directly prior to HPLC 
analysis was done at 4°C. 
To investigate the presence of glucuronidated 
CPT-11 metabolites, plasma samples obtained at 2 
and 5 h post-infusion were analyzed following 
enzyme-digestion as described previously with minor 
modifications [24]. Briefly, 250-1xl aliquots of plas- 
ma were incubated for 1 h at 37°C after addition of 
1000 units of [3-glucuronidase dissolved in 10 p~l of 
water. Next, samples were treated and extracted as 
outlined above for freshly thawed patient plasma. 
3. Results and discussion 
3.1. Chromatography and detection 
Chromatography was initially performed using 
Nova-Pak Radial-Pak ODS or Inertsil ODS reversed- 
phase analytical columns, in combination with mo- 
bile phases composed of ammonium acetate buffer 
and methanol or acetonitrile. Applying several meth- 
ods of sample pretreatment, blank human plasma 
samples contained remaining interfering substances 
around the retention times of CPT-11 or SN-38 
and/or sufficient separation between the analytes 
was associated with unacceptably long run times. 
Alternatively, analysis on a Hypersil ODS column 
with tetrabutylammonium sulphate as an ion-pairing 
agent added to the mobile phase resulted in no 
interfering substances in blank plasma samples com- 
bined with acceptable analyte separation (selectivity 
factors and resolution were always >-1.32 and 
-> 1.22, respectively). The composition and the pH of 
the mobile phases were selected in order to optimize 
separation factors and peak shapes of the analytes. 
At pH 5.50, the conversion of lactone to carboxylate 
was slow, while at a pH higher than 5.50, significant 
(on-column) conversion of lactone to carboxylate 
forms was observed. For the determination of CPT- 
11 and SN-38 using CPT as the internal standard, the 
fluorescence wavelength couple (excitation at 355 
nm and emission at 515 nm) was selected according 
to data published previously [22]. 
An organic-solvent extraction was chosen as the 
sample pretreatment procedure, as this procedure had 
resulted earlier in an effective clean-up of human 
plasma samples for the analysis of related corn- 
pounds, such as 9-aminocamptothecin [26], without 
the need for elaborate solid-phase xtraction tech- 
niques. Among the tested extraction and protein- 
precipitation procedures, a mixture of acetonitrile-n- 
butylchloride (1:4, v/v) for analysis of the lactone 
forms, and a mixture of aqueous perchloric acid- 
methanol (1:1, v/v) for analysis of the total forms 
resulted in minimal base-line distortion and optimal 
extraction recovery. Based on these results, valida- 
tion of the analytical methods was performed using 
the Hypersil ODS column, mobile phases containing 
tetrabutylammonium sulphate, and sample pretreat- 
ment procedures consisting of liquid-liquid extrac- 
tion with acetonitrile-n-butyl chloride or protein- 
precipitation with aqueous perchloric acid-methanol. 
3.2. Validation 
Blank human plasma samples from six different 
donors showed no interfering substances for both 
analytical procedures [Fig. 2A (lactone forms) and 
Fig. 3A (total forms)]. Interference analysis with 
drugs potentially co-administered with CPT-11, in- 
cluding acetaminophen, alizapride, codeine, dexa- 
methasone, domperidon, metoclopramide, morphine 
and ranitidine, did not reveal the presence of chro- 
matographic peaks with retention times similar to 
that of CPT-11 or SN-38. Typical chromatograms of 
plasma samples piked with known amounts of CPT- 
11 and SN-38 in the assay for the lactone and total 
forms are shown in Fig. 2B and Fig. 3B, respective- 
ly, in which the selectivity of the analytical pro- 
cedures for the analytes is shown by the sharp 
resolution of the peaks. The retention times of CPT- 
11, SN-38 and CPT in the assay of the lactone forms 
were 4.9, 8.1 and 6.5 min, while the retention times 
of CPT- 11 and SN-38 in the assay for the total forms 
were 8.3 and 15.0 min, with overall chromatographic 
run times of 10 and 20 min, respectively. 
At spiked concentrations of 0.5 and 2.0 ng/ml for 
lactone and total forms of CPT-11 and SN-38, 
respectively, the mean percentage deviation and the 
within-day precision were less than 20%. Therefore, 
these concentrations were estimated to be the LLQs. 
The lower value of the LLQ for the determination f
the lactones resulted from a concentration step in the 
sample pretreatment versus dilution of the sample in 
the assay for the total forms. At the upper limits of 
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Fig. 2. HPLC chromatograms of (A) a blank human plasma sample; (B) a spiked human plasma sample containing 100 ng/ml of CPT-I l 
lactone and SN-38 lactone and the internal standard CPT; (C) a patient plasma extract prepared immediately following the collection of a 
blood sample at 1 h post-infusion of CPT-11. The mobile phase was composed of methanol-0.1 M ammonium acetate containing 0.01 M 
tetrabutylammonium sulphate (40:60, v/v). Peaks identified with pure standards include CPT-11 lactone (I), SN-38 lactone (11) and CPT 
lactone (III). 
quantitation (ULQs; 15 ng/ml for the lactone forms 
and 200 ng/ml for the total forms), both the mean 
percentage deviation and the between-day precision 
were also less than 20%. Initially, the ULQ for the 
lactone forms of CPT-11 and SN-38 was arbitrarily 
defined as 20 ng/ml for both compounds, but this 
A B C 
l r I f  | I I  I 
0 10 lO  0 10 10 0 I0  10 
retention time (rain) 
Fig. 3. HPLC chromatograms of (A) a blank human plasma sample; (B) a spiked human plasma sample containing 2 ng/ml of CPT-I 1 total 
and SN-38 total; (C) a patient plasma extract prepared immediately following the collection of a blood sample at 1 h post-infusion of 
CPT-11. The mobile phase was composed of methanol-0.1 M ammonium acetate containing 0.01 M tetrabutylammonium sulphate (35:65, 
v/v). Peaks identified with pure standards include CPT-11 total (I) and SN-38 total (II). 
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Table 1 
Accuracy (%DEV), within-day precision (WDP) and between-day 
precision (BDP) of the lactone forms of CPT-11 and SN-38 in 
human plasma samples 
Compound Nominal conc. DEV Precision (%) 
(ng/ml) (%) 
WDP BDP 
CPT- I I 
SN-38 
0.5 +5.31 3.54 4.18 
2.0 - 4.90 3.29 2.32 
7.5 -0.98 0.77 1.92 
12 + 3.00 1.93 1.22 
120 +6.21 4.03 4.30 
5000 - 13.1 2.84 9.32 
0.5 -0.06 2.63 2.51 
2.0 + 2.20 1.92 2.05 
7.5 + 0.92 0.57 2.41 
12 + 1.70 0.95 2.05 
120 + 8.01 1.45 4.11 
5000 - 2.03 1.90 2.95 
was subsequently diminished to 15 ng/ml as a result 
of detector overload at higher drug concentrations. 
The results of the validation of the analytical 
methods in terms of precision and accuracy are listed 
in Tables 1 and 2. The use of the peak height in 
combination with a weight factor of 1/x 2 for the 
calibration resulted in minimal deviation from nomi- 
nal concentrations, with linear-regression correlation 
coefficients (Pearson's r) of ->0.995 in all validation 
runs. Both methods were shown to be accurate 
Table 2 
Accuracy (%DEV), within-day precision (WDP) and between-day 
precision (BDP) of the total forms of CPT-11 and SN-38 in 
human plasma samples 
Compound Nominal conc. DEV Precision (%) 
(ng/ml) (%) 
WDP BDP 
CPT-11 
SN-38 
2.0 + 6.75 14.3 4.25 
10 -7.87 3.38 3.08 
75 -2.60 2.27 2.35 
150 + 2.93 1.75 2.46 
750 + 0.28 1.75 2.22 
2.0 +0.32 12.4 
10 + 9.57 2.52 2.89 
75 + 9.90 2.56 2.62 
150 + 12.2 2.08 2.79 
750 + 7.98 1.58 2.78 
a No additional variation was observed as a result of performing 
the assay in different runs. 
(average accuracy at four tested concentrations was 
between - 13.1 and + 12.2%) and precise (between- 
day and within-day variation were within 15%). The 
mean overall extraction efficiencies were 91.5___3.9% 
(CPT-11 lactone; n=48), 87.5---8.7% (SN-38 lac- 
tone; n=48),  85.3---5.3% (CPT-11 total; n=47),  
99.3_+9.2% (SN-38 total; n=47) and 88.1_+5.1% 
(CPT lactone, used as internal standard; n=48) and 
were independent of the concentration. Data from the 
stability studies indicated that the lactone forms of 
CPT-11 and SN-38 were unstable after storage at 
room temperature or at 37°C. This instability neces- 
sitates rapid freezing of clinical samples after blood 
collection to prevent significant degradation i to the 
carboxylate forms. Lactone and total forms of CPT- 
11 and SN-38 were stable for at least two months 
after storage at -80°C. Repeated quick freeze-thaw- 
ing cycles (n=5) had no influence on the stability. 
Processed plasma samples were also found to be 
stable at room temperature upon standing in the 
autosampler t ay for at least 20 h, allowing samples 
to be processed during the day with consecutive 
analysis overnight. 
3.3. Patient samples 
The described analytical methods were applied in 
our institute to a phase I and pharmacokinetic study 
of CPT-11 in combination with cisplatin in patients 
with advanced solid cancer. Immediately after sam- 
piing, tubes were immersed briefly into ice-water 
kept at the bedside, and centrifuged immediately and 
stored at -20°C to prevent significant degradation of 
the sample. Plasma collected from patients prior to 
drug administration were free from interfering en- 
dogenous compounds. However, several chromato- 
graphic peaks could be detected in processed sam- 
ples obtained from patients after drug administration 
that were not present in pre-infusion specimens (Fig. 
2C and Fig. 3C). In addition to the lactone forms of 
CPT-I 1, SN-38 and CPT in Fig. 2C, and the total 
forms of CPT-11 and SN-38 in Fig. 3C (positively 
identified with the aid of pure reference standards), 
several other major peaks were detected at 3.9, 5.2, 
5.5, 6.0, 7.4 and 9.9 min in the assay for the total 
forms (Fig. 3C). Treatment of the plasma sample 
displayed in Fig. 3C with [3-glucuronidase r sulted in 
the disappearance of the peaks at 3.9 and 7.4 min, 
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and a concomitant increase in the SN-38 peak area 
which is indicative of the presence of a [3-glucuro- 
nide conjugate of SN-38 (data not shown) [24,25]. 
The identity of other chromatographic peaks remains 
to be elucidated. Similar HPLC chromatographic 
profiles were obtained with plasma specimens from 
other cancer patients. 
Plasma concentration-time curves of the lactone 
and carboxylate forms of CPT-11 and SN- 38 are 
displayed in Fig. 4. Concentrations of the lactone 
forms could be readily estimated from protein-free 
extracts after solvent extraction, whereas acidifica- 
tion of the samples, reconverting the carboxylate into 
the corresponding lactone, enabled determination of 
the total forms. The carboxylate forms of CPT-11 
and SN-38 were quantitated from the difference in 
concentration of total and lactone forms. This in- 
direct determination is justified as approximation of 
these concentrations and is defined by a combination 
of both methods, resulting in levels also within 
___20% of the nominal values. The observed three- 
exponential decline of the compounds, as well as the 
post-infusion predominance of the CPT-11 carbox- 
ylate form is in agreement with previous inves- 
tigations [24,27]. The pharmacokinetic profile (e.g. 
the terminal elimination half-life) of the as yet 
unidentified metabolites appeared to be similar to 
that of the parent drug (PdB and AS, unpublished 
data). 
4.  Conc lus ion  
Thoroughly validated analytical methods for the 
determination of CPT-11 and SN-38 in both their 
lactone and carboxylate forms in human plasma have 
been described. Although, over the last few years, 
various analytical procedures have been developed 
for the simultaneous determination of lactone and 
carboxylate forms of camptothecin analogues 
[22,28], clinical applicability of these assays is 
hampered by stability problems associated with 
lactone-carboxylate interconversion, which necessi- 
tates manual sample injection. In fact, our attempts 
to develop such a method for CPT-11 and SN-38 
have been unsuccessful as a result of lack in 
stability, specificity and selectivity, and a poor 
extraction efficiency of the carboxylate forms. Ulti- 
mately, two methods were used in combination, with 
sample pretreatment procedures based on single 
100 
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Fig. 4. Plasma concentration-time curves of CPT-11 lactone (closed circle), CPT-I 1 carboxylate (open circle), SN-38 lactone (closed square) 
and SN-38 carboxylate (open square) in a patient after a 90-min intravenous infusion of 200 mg/m 2of CPT-11. Pharmacokinetic curves 
were fitted to a three-compartment odel using the MWWharm software package (MediWare, Groningen, The Netherlands). 
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solvent extractions. The result ing methodolog ies  
provide superior  sensit iv ity as compared to previous-  
ly descr ibed assays, with LLQs  of  0.5 and 2.0 ng /ml  
for the lactone and total forms, respectively.  Current-  
ly, e lucidat ion of the structural identity and bio- 
chemica l  propert ies of  the unknown metabol i tes is 
under  further invest igat ion.  
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